Market Closed -
Other stock markets
|
After market 12:45:07 | |||
141.4 EUR | -0.07% | 141.4 | -0.04% |
06:13pm | European Equities Close Higher in Monday Trading; Ryanair May Have to Lower Ticket Prices | MT |
04:40pm | Global markets live: Apple, Tesla, Pfizer, AstraZeneca, Microsoft... |
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
- The firm trades with high earnings multiples: 22.09 times its 2024 earnings per share.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+15.85% | 239B | - | ||
+33.90% | 693B | C+ | ||
+29.39% | 584B | B | ||
-2.85% | 372B | C+ | ||
+20.57% | 332B | B- | ||
+6.74% | 294B | C+ | ||
-3.03% | 211B | A+ | ||
+10.02% | 210B | B- | ||
+8.98% | 168B | C+ | ||
-0.50% | 162B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- AZN Stock
- ZEG Stock
- Ratings AstraZeneca PLC